Samsung Bioepis Reports Q3 Sales Growth, Despite ‘Absence Of Milestones’
The Firm Also Released Its Third Quarter 2024 US Biosimilar Market Report
After a “remarkable performance” in Q2, Samsung Bioepis enjoyed a calm, but still profitable, third quarter.
